Inventiva vs Entrada Therapeutics
IVA and TRDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IVA and TRDA compare
Inventiva grew revenue faster over the last twelve months (−51.3% versus −93.5% for Entrada Therapeutics).
Entrada Therapeutics scores higher on the StockData Score (6 against 1 for Inventiva), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IVA | TRDA |
|---|---|---|
| Size and price | ||
| Market cap | – | $198M |
| Share price | $3.68 | $5.09 |
| Change, 1 year | −9.1% | −36.5% |
| Change, 5 years | −72.1% | −84.5% |
| Beta (5Y) | 0.83 | 0.96 |
| Employees | 77 | 152 |
| StockData Score | ||
| Total score | 1 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 49.8× |
| P/B | – | 1.0× |
| FCF yield | – | −68.8% |
| Growth | ||
| Revenue growth (TTM) | −51.3% (better) | −93.5% |
| Revenue growth, 5Y average | 64.5% | – |
| Profitability | ||
| Operating margin | −3146% (better) | −4304% |
| Net margin | – | −4058% |
| FCF margin | – | −3428% |
| Return on equity | – | −59.9% |
| Return on invested capital | – | −1406% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −0.7× | – |
| Current ratio | 3.81 | 7.85 (better) |
| Altman Z-score | – | −1.64 |
| Piotroski F-score | – | 2 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 45.2% | 75.6% |
| Held by insiders | 24.7% | 14.8% |
| Insider net buying, 12 months | – | −$11.5M |
| Short interest, % of float | – | 8.5% |
Go deeper
- IVA stock overview
- IVA income statement
- IVA valuation and score
- TRDA stock overview
- TRDA income statement
- TRDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.